Codice:
E023052
ISSN:
0006-4971
Dati Generali
Pubblicazioni (764)
A method for immunomagnetic separation of CD34+ canine hematopoietic progenitors for stem cell transplantation.
Contributo in Atti di convegnoAUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL
Contributo in Atti di convegnoAdenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment
Contributo in Atti di convegnoAdenovirus infections in patients undergoing bone marrow transplantation.
Contributo in Atti di convegnoAdenovirus nephritis: A newly described clinical-pathological entity in bone marrow transplantation.
Contributo in Atti di convegnoAllogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged 60 Years.
Contributo in Atti di convegnoAn Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma.
Contributo in Atti di convegnoAn entirely novel form of a thalassemia in patients from the south pacific linked to chromosome 16
Contributo in Atti di convegnoAssessing proteostasis and proteasome stress in light chain amyloidosis
Contributo in Atti di convegnoBalancing act for elderly myeloma.
ArticoloCharacteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases
Contributo in Atti di convegnoCodanin-1 Mutations In Congenital Dyserythropoietic Anemia Type 1 Affect HP1 alpha Localization In Erythroblasts
Contributo in Atti di convegnoComparison of clinical expression of type 2 (juvenile) and type 3 hemochromatosis. RID B-1183-2008
Contributo in Atti di convegnoComparison of clinical expression of type 2 (juvenile) and type 3 hemochromatosis. RID B-1183-2008
Contributo in Atti di convegnoCyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome
Contributo in Atti di convegnoDefibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.
Contributo in Atti di convegnoDendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells
Contributo in Atti di convegnoDirect Assessment of Proteasomal Degradation as a Potential Predictor of Responsiveness to Bortezomib in Multiple Myeloma
Contributo in Atti di convegnoDiscovering Regulatory SNPs by Genome-Wide Analysis of Differential Scl/TAL-1 Occupancy in Human Primary Erythroid Cells
Contributo in Atti di convegnoDisease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies.
Contributo in Atti di convegnoEarly Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography.
Contributo in Atti di convegnoEvaluation of a panel of monoclonal antibodies (MAB) that recognize canine CD34.
Contributo in Atti di convegnoEx vivo expanded, retrovirally transduced cytotoxin T-lymphocytes (CTL) enhance engraftment of DLA-haploidentical marrow.
Contributo in Atti di convegnoEx vivo expansion of canine dendritic cells from CD34(+) bone marrow progenitor cells
Contributo in Atti di convegnoFoxO transcription factor is delocalized and inactivated in acute myeloid leukaemia patients.
Contributo in Atti di convegnoHIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target
Contributo in Atti di convegnoHigh Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease
Contributo in Atti di convegnoHigh Prevalence of Hyperhomocysteine in Retinal Vein Occlusion
Contributo in Atti di convegnoHow I treat fragile myeloma patients
ArticoloIMMUNE RECONSTITUTION AFTER NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Contributo in Atti di convegnoIN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT
Contributo in Atti di convegnoINTERMEDIATE-DOSE CYCLOPHOSPHAMIDE FOLLOWED BY INTERFERON-ALPHA-2B AND PREDNISONE MAINTENANCE THERAPY FOR REFRACTORY MYELOMA
Contributo in Atti di convegnoIdentification of a gain-of-function SNP causing a new model of alpha-thalassaemia.
Contributo in Atti di convegnoImmune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
Contributo in Atti di convegnoImmunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2
Contributo in Atti di convegnoImpact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR
Contributo in Atti di convegnoIn vivo tracking of canine CD34(+)Lin(-) and CD34(-)Lin(-) hematopoietic cells transduced with retroviral vectors.
Contributo in Atti di convegnoIt’s in your (peripheral) blood
ArticoloKAPOSI'S SARCOMA DUE TO ENDOGENOUS HHV-8 REATVIATION IN NON MYELOABLETIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Contributo in Atti di convegnoLOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING FOR ADVANCED HEMATOLOGICAL MALIGNANCIES: A MULTICENTER EXPIRIENCE
Contributo in Atti di convegnoLong-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Contributo in Atti di convegnoLow dose TBI based non myeloablative allografting for advanced hematological malignancies: A multicenter experience.
Contributo in Atti di convegnoLow-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma
Contributo in Atti di convegnoMLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation
Contributo in Atti di convegnoMOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE
Contributo in Atti di convegnoMULTIPLE MYELOMA: DIFFERENT PHENOTYPIC CHARACTERISTICS ARE SHOWN BY PLASMA CELLS FROM LEUKAPHERESIS AND BONE MARROW
Contributo in Atti di convegnoMYELOMA CELLS DRIVE THE MATURATION OF DENDRITIC CELLS VERSUS A TH2-PROMOTING PHENOTYPE WHICH IMPAIRS T-CELL ACTIVATION
Contributo in Atti di convegnoMet Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents
Contributo in Atti di convegnoMyeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation.
Contributo in Atti di convegnoNF-KB inhibitors are new approaches in the molecular therapy of leukemias
Contributo in Atti di convegnoNPM1 mutations are responsible for better response to induction therapy in AML patients through the inactivation of NF-kB
Contributo in Atti di convegnoNck beta adapter protein coordinates Bcr-Abl/Sam68 intermolecular interaction
Contributo in Atti di convegnoNon-HFE hemochromatosis: insights into regulation on iron metabolisms from novel iron loading disorders.
Contributo in Atti di convegnoNon-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.
Contributo in Atti di convegnoNonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).
Contributo in Atti di convegnoNonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia
Contributo in Atti di convegnoOral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.
Contributo in Atti di convegnoOral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.
Contributo in Atti di convegnoPhenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells
Contributo in Atti di convegnoProteasome stress causes apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Contributo in Atti di convegnoREAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS
Contributo in Atti di convegnoReduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years.
Contributo in Atti di convegnoRegulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions
Contributo in Atti di convegnoRelapse risk after nonmyeloablative hematopoietic cell transplantation for malignant diseases.
Contributo in Atti di convegnoRisk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allogeneic stem cell transplant
Contributo in Atti di convegnoSLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy
Contributo in Atti di convegnoSecondary failure of platelet recovery in hematopoietic stem cell transplantation (HSCT).
Contributo in Atti di convegnoSequential cyclophosphamide-melphalan (CM) with circulating progenitor cell (CPC) support in multiple myeloma
Contributo in Atti di convegnoSodium valproate enhances Imatinib induced apoptosis and growth arrest in Bcr-Abl cell lines
Contributo in Atti di convegnoTandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.
Contributo in Atti di convegnoTelomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients
Contributo in Atti di convegnoThe IKK inhibitor PS1145 allows to overcome Imatinib resistance
Contributo in Atti di convegnoThe Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.
Contributo in Atti di convegnoThe meyloablative and immunosuppressive properties of treosulfan in mice
Contributo in Atti di convegnoThe quantitaive assessment of WT1 gene expression as a method to predict response to STI571 therapy in CML patients
Contributo in Atti di convegnoThe ying and yang of Activin A
ArticoloThymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies
Contributo in Atti di convegnoVelcadeTM Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.
Contributo in Atti di convegnoWT-1 expression in childhood acute leukemias
Contributo in Atti di convegnoWT1 Expression in acute myeloid leukaemia:a useful marker for improving therapy response evaluation.
Contributo in Atti di convegnoNo Results Found